AN2 Therapeutics, Inc. Accretion (Amortization) of Discounts and Premiums, Investments
AN2 Therapeutics, Inc. (ANTX) reported Accretion (Amortization) of Discounts and Premiums, Investments of $175.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-11
- AN2 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-06-30 was $94.00K, a 68.56% decline year-over-year.
- AN2 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-03-31 was $81.00K, a 81.72% decline year-over-year.
- AN2 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-12-31 was $117.00K, a 79.37% decline year-over-year.
- AN2 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-09-30 was $211.00K, a 71.14% decline year-over-year.
- AN2 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $1.07M, a 67.37% decline from fiscal 2024.
- AN2 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $3.28M, a 14.85% increase from fiscal 2023.
- AN2 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $2.85M, a 312.57% increase from fiscal 2022.
- AN2 Therapeutics, Inc. accretion (amortization) of discounts and premiums, investments for fiscal 2022 was $692.00K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $175.00K 10-Q · filed 2026-08-11 | $292.00K derived: sum of 3 quarters · filed 2026-08-11 | $503.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $81.00K 10-Q · filed 2026-05-11 | $198.00K derived: sum of 2 quarters · filed 2026-05-11 | $409.00K derived: sum of 3 quarters · filed 2026-05-11 | $708.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $328.00K derived: sum of 2 quarters · filed 2026-03-17 | $627.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.07M 10-K · filed 2026-03-17 |
| 2025-09-30 | $211.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $510.00K derived: sum of 2 quarters · filed 2026-08-11 | $953.00K 10-Q · filed 2025-11-12 | $1.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $299.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $742.00K 10-Q · filed 2026-08-11 | $1.31M derived: sum of 3 quarters · filed 2026-08-11 | $2.04M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $443.00K 10-Q · filed 2026-05-11 | $1.01M derived: sum of 2 quarters · filed 2026-05-11 | $1.74M derived: sum of 3 quarters · filed 2026-05-11 | $2.63M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $567.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.30M derived: sum of 2 quarters · filed 2026-03-17 | $2.19M derived: sum of 3 quarters · filed 2026-03-17 | $3.28M 10-K · filed 2026-03-17 |
| 2024-09-30 | $731.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.62M derived: sum of 2 quarters · filed 2025-11-12 | $2.71M 10-Q · filed 2025-11-12 | $4.02M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $890.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $1.98M 10-Q · filed 2025-08-12 | $3.29M derived: sum of 3 quarters · filed 2025-08-12 | $3.94M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.09M 10-Q · filed 2025-05-13 | $2.40M derived: sum of 2 quarters · filed 2025-05-13 | $3.05M derived: sum of 3 quarters · filed 2025-05-13 | $3.51M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $1.96M derived: sum of 2 quarters · filed 2025-03-25 | $2.42M derived: sum of 3 quarters · filed 2025-03-25 | $2.85M 10-K · filed 2025-03-25 |
| 2023-09-30 | $653.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.11M derived: sum of 2 quarters · filed 2024-11-13 | $1.55M 10-Q · filed 2024-11-13 | $1.92M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $461.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $896.00K 10-Q · filed 2024-08-13 | $1.27M derived: sum of 3 quarters · filed 2024-08-13 | $1.52M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $435.00K 10-Q · filed 2024-05-14 | $810.00K derived: sum of 2 quarters · filed 2024-05-14 | $1.05M derived: sum of 3 quarters · filed 2024-05-14 | $1.13M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $375.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $620.00K derived: sum of 2 quarters · filed 2024-03-29 | $693.00K derived: sum of 3 quarters · filed 2024-03-29 | $692.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $245.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $318.00K derived: sum of 2 quarters · filed 2023-11-09 | $317.00K 10-Q · filed 2023-11-09 | $294.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $73.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $72.00K 10-Q · filed 2023-08-10 | $49.00K derived: sum of 3 quarters · filed 2023-08-10 | $30.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$1.00K 10-Q · filed 2023-05-11 | -$24.00K derived: sum of 2 quarters · filed 2023-05-11 | -$43.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$42.00K derived: sum of 2 quarters · filed 2023-03-29 | -$53.00K 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$30.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | -$11.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |